Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer

PURPOSE: Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) –mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Liu, Joyce F., Ray-Coquard, Isabelle, Selle, Frederic, Poveda, Andrés M., Cibula, David, Hirte, Hal, Hilpert, Felix, Raspagliesi, Francesco, Gladieff, Laurence, Harter, Philipp, Siena, Salvatore, del Campo, Josep Maria, Tabah-Fisch, Isabelle, Pearlberg, Joseph, Moyo, Victor, Riahi, Kaveh, Nering, Rachel, Kubasek, William, Adiwijaya, Bambang, Czibere, Akos, Naumann, R. Wendel, Coleman, Robert L., Vergote, Ignace, MacBeath, Gavin, Pujade-Lauraine, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562430/
https://ncbi.nlm.nih.gov/pubmed/27998236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.1891
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados